新华制药(000756) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥1,299,255,096.08, representing a year-on-year increase of 2.14%[8] - Net profit attributable to shareholders of the listed company was ¥91,126,989.08, up 30.24% compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses was ¥74,242,532.89, an increase of 33.61% year-on-year[8] - Basic earnings per share were ¥0.15, up 36.36% from the same period last year[8] - The company's net profit attributable to shareholders for Q3 2019 was RMB 91,126,989.08, up 30.24% year-on-year, while for the first nine months of 2019, it was RMB 238,601,004.25, an increase of 23.42%[24] - The company's total comprehensive income for the third quarter was CNY 70,852,398.79, down from CNY 94,010,637.54 in the previous year[54] - The total profit for the period was CNY 309,560,523.42, compared to CNY 257,035,358.39 in the previous year, marking an increase of 20.5%[63] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,049,248,030.04, an increase of 2.25% compared to the end of the previous year[8] - Total liabilities as of September 30, 2019, were CNY 3,030,939,469.42, a decrease of 2.8% from CNY 3,119,603,287.55[41] - The company's total assets reached CNY 6,049,248,030.04, an increase of 2.2% from CNY 5,916,156,319.63[42] - The equity attributable to shareholders of the parent company increased to CNY 2,893,341,218.13, up from CNY 2,687,248,318.01, reflecting an increase of 7.7%[42] - The company's total assets at the end of the reporting period were CNY 4,399,154,718.03, an increase from CNY 3,959,689,652.51 in the previous year[56] - Total liabilities for Q3 2019 were CNY 2,624,581,126.56, a decrease from CNY 2,708,043,644.79 in Q3 2018, representing a reduction of approximately 3.1%[47] Cash Flow - The net cash flow from operating activities reached ¥293,388,996.13, showing a significant increase of 105.40% compared to the previous year[8] - The net cash flow from operating activities for the current period is ¥293,388,996.13, an increase of 105.5% compared to ¥142,837,402.06 in the previous period[68] - Total cash inflow from operating activities reached ¥3,712,895,280.93, up from ¥3,157,044,394.26, reflecting a growth of 17.5%[66] - Cash outflow from operating activities totaled ¥3,419,506,284.80, compared to ¥3,014,206,992.20 in the previous period, indicating an increase of 13.4%[68] - The cash inflow from sales of goods and services was ¥3,581,713,714.50, an increase of 17.2% from ¥3,055,569,904.81 in the previous period[66] Investments and Equity - Long-term equity investments increased by 311.32% to RMB 80,595,811.75 as of September 30, 2019, due to the acquisition of a 30% stake in a joint venture[22] - The company reported a significant increase in other equity instrument investments to CNY 219,144,640.00 from CNY 189,739,168.00, marking a growth of 15.5%[40] - Long-term borrowings rose to CNY 691,712,411.56, an increase of 32.4% from CNY 522,643,436.60[41] - The company reported fixed assets valued at CNY 2,631,152,561.89 as of the reporting date[77] Shareholder Information - The total number of shareholders at the end of the reporting period was 31,317, with the top ten shareholders holding a combined 68.82% of the shares[11] - The company's equity totaled CNY 2,500,930,029.93, with retained earnings at CNY 821,524,409.95[84] Expenses - Management expenses for Q3 2019 were RMB 68,415,253.99, up 36.80% year-on-year, primarily due to increased employee compensation and depreciation costs[22] - The company's financial expenses for the first nine months of 2019 rose by 73.46% to RMB 30,976,862.40, mainly due to reduced exchange gains from currency fluctuations[22] - Research and development expenses for Q3 2019 were CNY 49,532,460.28, down from CNY 54,006,848.91 in Q3 2018, indicating a decrease of approximately 8.5%[49] - The company reported a decrease in sales expenses to CNY 176,798,596.59 in Q3 2019 from CNY 163,457,382.85 in Q3 2018, which is an increase of about 8.1%[49]